These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
138 related articles for article (PubMed ID: 21441045)
1. Clinicopathologic features and determinants of Gleason score of prostate cancer in Ghanaian men. Yarney J; Vanderpuye V; Mensah J Urol Oncol; 2013 Apr; 31(3):325-30. PubMed ID: 21441045 [TBL] [Abstract][Full Text] [Related]
2. Serum insulin level, disease stage, prostate specific antigen (PSA) and Gleason score in prostate cancer. Lehrer S; Diamond EJ; Stagger S; Stone NN; Stock RG Br J Cancer; 2002 Sep; 87(7):726-8. PubMed ID: 12232754 [TBL] [Abstract][Full Text] [Related]
3. [Staging of prostate cancer: value of the combined information of endorectal MRI, biopsy Gleason score, and preoperative PSA level]. Wetter A; Ajdukovic AN; Fliessbach K; Lehnert T; Engl T; Jacobi V; Vogl TJ Rofo; 2006 Apr; 178(4):385-90. PubMed ID: 16607587 [TBL] [Abstract][Full Text] [Related]
4. Association of percent positive prostate biopsies and perineural invasion with biochemical outcome after external beam radiotherapy for localized prostate cancer. Wong WW; Schild SE; Vora SA; Halyard MY Int J Radiat Oncol Biol Phys; 2004 Sep; 60(1):24-9. PubMed ID: 15337536 [TBL] [Abstract][Full Text] [Related]
5. The ability of prostate-specific antigen (PSA) density to predict an upgrade in Gleason score between initial prostate biopsy and prostatectomy diminishes with increasing tumour grade due to reduced PSA secretion per unit tumour volume. Corcoran NM; Casey RG; Hong MK; Pedersen J; Connolly S; Peters J; Harewood L; Gleave ME; Costello AJ; Hovens CM; Goldenberg SL BJU Int; 2012 Jul; 110(1):36-42. PubMed ID: 22085203 [TBL] [Abstract][Full Text] [Related]
6. Factors affecting recurrence rates after prostatectomy or radiotherapy in localized prostate carcinoma patients with biopsy Gleason score 8 or above. Kupelian PA; Buchsbaum JC; Elshaikh M; Reddy CA; Zippe C; Klein EA Cancer; 2002 Dec; 95(11):2302-7. PubMed ID: 12436435 [TBL] [Abstract][Full Text] [Related]
8. Advancing age within established Gleason score categories and the risk of prostate cancer-specific mortality (PCSM). Russo AL; Chen MH; Aizer AA; Hattangadi JA; D'Amico AV BJU Int; 2012 Oct; 110(7):973-9. PubMed ID: 22954029 [TBL] [Abstract][Full Text] [Related]
9. [Clinical value of prostate specific antigen screening in early detection of prostate cancer]. Hua LX; Qiao D; Song NH; Feng NH; Yang J; Zhang JX; Chen JG; Zhang W; Sui YG; Wu HF Zhonghua Zhong Liu Za Zhi; 2009 Sep; 31(9):705-9. PubMed ID: 20021870 [TBL] [Abstract][Full Text] [Related]
10. Early detection of high-grade prostate cancer using digital rectal examination (DRE) in men with a prostate-specific antigen level of <2.5 ng/mL and the risk of death. Hattangadi JA; Chen MH; D'Amico AV BJU Int; 2012 Dec; 110(11):1636-41. PubMed ID: 22757982 [TBL] [Abstract][Full Text] [Related]
11. Pathological features of Gleason score 6 prostate cancers in the low and intermediate range of prostate-specific antigen level: is there a difference? Pelzer AE; Colleselli D; Bektic J; Steiner E; Ramoner R; Mitterberger M; Schwentner C; Schaefer G; Ongarello S; Bartsch G; Horninger W BJU Int; 2008 Apr; 101(7):822-5. PubMed ID: 18261154 [TBL] [Abstract][Full Text] [Related]
12. Prediagnostic prostate-specific antigen velocity and probability of detecting high-grade prostate cancer. Krejcarek SC; Chen MH; Renshaw AA; Loffredo M; Sussman B; D'Amico AV Urology; 2007 Mar; 69(3):515-9. PubMed ID: 17382156 [TBL] [Abstract][Full Text] [Related]
13. Prostate-specific antigen velocity and prostate cancer gleason grade and stage. Pinsky PF; Andriole G; Crawford ED; Chia D; Kramer BS; Grubb R; Greenlee R; Gohagan JK Cancer; 2007 Apr; 109(8):1689-95. PubMed ID: 17330856 [TBL] [Abstract][Full Text] [Related]
14. Prognostic factors for clinically localized prostate carcinoma: analysis of 938 patients irradiated in the prostate specific antigen era. Zagars GK; Pollack A; von Eschenbach AC Cancer; 1997 Apr; 79(7):1370-80. PubMed ID: 9083160 [TBL] [Abstract][Full Text] [Related]
15. Laparoscopic pelvic lymph node dissection in the staging of prostate cancer. Stone NN; Stock RG Mt Sinai J Med; 1999 Jan; 66(1):26-30. PubMed ID: 9989102 [TBL] [Abstract][Full Text] [Related]
16. Improved risk stratification for biochemical recurrence after radical prostatectomy using a novel risk group system based on prostate specific antigen density and biopsy Gleason score. Freedland SJ; Wieder JA; Jack GS; Dorey F; deKernion JB; Aronson WJ J Urol; 2002 Jul; 168(1):110-5. PubMed ID: 12050502 [TBL] [Abstract][Full Text] [Related]
17. Lack of association of prostate carcinoma nuclear grading with prostate specific antigen recurrence after radical prostatectomy. Zhou M; Hayasaka S; Taylor JM; Shah R; Proverbs-Singh T; Manley S; Rubin MA J Urol; 2001 Dec; 166(6):2193-7. PubMed ID: 11696734 [TBL] [Abstract][Full Text] [Related]
18. Update on Memorial Sloan-Kettering Cancer Center studies of neoadjuvant hormonal therapy for prostate cancer. Fair WR; Betancourt JE Mol Urol; 2000; 4(3):241-8;discussion 249-50. PubMed ID: 11062380 [TBL] [Abstract][Full Text] [Related]
19. Impact of the percentage of positive prostate cores on prostate cancer-specific mortality for patients with low or favorable intermediate-risk disease. D'Amico AV; Renshaw AA; Cote K; Hurwitz M; Beard C; Loffredo M; Chen MH J Clin Oncol; 2004 Sep; 22(18):3726-32. PubMed ID: 15365069 [TBL] [Abstract][Full Text] [Related]
20. Pretreatment predictors of time to cancer specific death after prostate specific antigen failure. D'Amico AV; Cote K; Loffredo M; Renshaw AA; Chen MH J Urol; 2003 Apr; 169(4):1320-4. PubMed ID: 12629352 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]